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Considerable knowledge of the ontogeny of the endo-
crine pancreas has been gained in recent years, mainly
through the use of two complementary genetic ap-
proaches in transgenic mice: gene inactivation or over-
expression (to assess gene function) and genetic labeling
of precursor cells (to determine cell lineages). In recent
years, in vivo Cre/loxP-based direct cell tracing expe-
riments show that (i) all pancreatic cells differentiate
from pdx1-expressing precursors, (ii) p48 is involved
in the exocrine and endocrine pancreatic lineages, (iii)
islet endocrine cells derive from ngn3-expressing pro-
genitor cells, and (iv) insulin cells do not derive from glu-
cagon-expressing progenitors. Lineage analyses allow
the identification of progenitor cells from which mature
cell types differentiate. Once identified, such progeni-
tors can be labeled and isolated, and their differentiation
and gene expression profiles studied in vitro. Under-
standing pancreatic cell lineages is highly relevant for
future cell replacement therapies in diabetic patients,
helping to define the identity of putative (endodermal)
pancreatic stem cells.
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loxP; stem cells.
Pancreas Differentiation and Morphogenesis
The pancreas contains endocrine and exocrine cells. The
exocrine pancreas represents more than 95% of the gland;
it is composed of the acinar secretory cells, producing dige-
stive enzymes such as amylase, and the excretory ducts. The
endocrine cells of the pancreas form clusters embedded in
the exocrine tissue: the islets of Langerhans. Islets are com-
posed of four types of endocrine cells: the centrally located
 cells produce insulin, while the peripheral , , and PP
cells produce glucagon, somatostatin, and pancreatic poly-
peptide, respectively.
Pancreas Organogenesis
The pancreas initially develops from distinct dorsal and
ventral primordia that later fuse to form the mature organ.
This involves a sequential cascade of inductive events in
association with the activation of specific transcription fac-
tors. Pancreatic buds evaginate from the early foregut endo-
derm caudally to the stomach primordium, near the pro-
spective liver: the molecular determinants that define the
position of the pancreas along the anterior–posterior axis
remain unknown (1,2). The first hormone-containing cells
found in early primordia are epithelial and appear located
exclusively within the walls of the embryonic ducts or cords.
Contrary to what is observed in adult islets, these cells fre-
quently contain simultaneously more than one hormone; this
has suggested the existence of a common precursor cell for
all four islet cell types. For instance, because glucagon-con-
taining cells are the first to differentiate in early buds, and
given the presence of cells co-expressing glucagon and insu-
lin, it was proposed that mature insulin cells derive from
glucagon progenitors (3).
Commitment to a pancreatic fate occurs as early as embry-
onic d 8–8.5 (E8–E8.5) in mice. Permissive signals released
from adjacent mesodermal structures, including the noto-
chord, aorta, and cardiac mesoderm, are important for induc-
tion of the pancreatic program. The notochord induces
dorsal pancreas development through the inhibition of SHH
(Sonic hedgehog) in pre-pancreatic dorsal endoderm. Shh
is expressed in the early gut endoderm and has been shown
to pattern it (1,4–6). This Shh repression, which appears to
be by activin B and FGF2 (7), is permissive for the expres-
sion of Pdx1. Shh is also repressed, and Pdx1 expressed, in
the ventral pre-pancreatic endoderm.
It is intriguing that the same mesenchymal morphogens
have opposite inductive effects on the dorsal and ventral pan-
creas: in the absence of dorsal mesoderm, the dorsal endo-
derm expresses liver markers, whereas, without ventral meso-
derm (i.e., cardiac mesoderm and septum transversum), the
ventral endoderm “defaults” to pancreas instead of liver.
Indeed, signals from ventral mesoderm (FGFs) promote hep-
atic development (8).
The first indication of morphogenesis occurs at E9.5,
when the dorsal mesenchyme condenses and the underly-
ing endoderm evaginates to form a recognizable dorsal pan-
creatic bud; the ventral bud appears one day later (E10.5).
Both buds subsequently proliferate, stimulated by mesen-
chymal signals, to form multiple branches and fuse together
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by d E17 (the ventral bud translocates to the dorsal side
during gut rotation) to make a functional organ.
Timing of Appearance
of Differentiated Endocrine Phenotypes
In mice, the first differentiated cells, as determined by
immunofluorescence, are glucagon-producing cells; they
are already detectable at E9.5 in the dorsal pancreatic bud
and one day later in the ventral, whereas the first insulin-
producing cells are present the following day (E10.5–E11)
in both primordia. After branching, at E13.5, somatostatin-
positive cells are detectable in both buds, and the exocrine
pancreas containing well-formed acini begins to differenti-
ate at E14.5. Three days prior to birth, at E16.5, PP-secret-
ing cells are also detected, and the first islets of Langerhans
are formed at E18.5 (9).
The timing of hormone gene expression was also deter-
mined by RT-PCR of total RNAs extracted from pancrea-
tic buds and surrounding tissues at different developmental
stages (9,10). Glucagon and somatostatin mRNAs are
found very early (E8.5–E9), probably from extrapancreatic
sources; insulin I transcript was detected in E10.5 buds,
whereas insulin II was found only 1 d later. Surprisingly,
PP mRNA is detected from E10.5 onward, thus indicating
PP gene expression early in the developing mouse pancreas.
Islet Organogenesis
Analysis of endocrine cells in situ suggests three major
patterns of endocrine cell localization in embryonic pancreas.
The earliest hormone-containing cells are individual cells
located within the epithelium of pancreatic ducts or cords.
In both dorsal and ventral buds, the majority of these endo-
crine cells contain more than one hormone, and this co-
localization occurs at the secretory granule level: different
hormones are co-stored within the same granules (9). Subse-
quently, these cells migrate into the surrounding connective
tissue, forming clusters of endocrine cells in the pancreatic
interstitia. This process involves interactions between cells
through adhesion molecules and active proteolysis of the
extracellular matrix (11) [reviewed by Johansson and Grapin-
Botton (1)]. For instance, collagen IV, which is a compo-
nent of basement membranes, is absent at the places where
these first endocrine cells appear (Fig. 1). Finally, starting
on E18.5, as indicated above, typical islets are formed with
centrally located  cells and with the adult “one cell–one
hormone” phenotype (9).
Analysis of Cell Lineage Analyses:
A Brief Historical Overview
The origin of multicellularity during evolution required,
and allowed, that all (or almost all), cells forming a particu-
lar organism become highly specialized in order to fulfill
particular tasks. Yet all these different cell types, more than
two hundred in a typical mammalian body, derive and dif-
ferentiate progressively from one single and unique totipo-
tent cell: the zygote. Development of metazoan organisms
from one-celled embryos is either “mosaic,” meaning that
early cell divisions are restrictive—the young blastomeres
quickly losing their developmental potential—or “regula-
tive,” as in mammals, for each blastomere remains pluripo-
tent until later stages, when interactions between neighbor
cells determine their respective destiny. Understanding these
developmental processes implies knowledge of the precise
lineages of cells; the observer therefore requires a method
to reliably identify particular cells and all of their progeny,
to reveal their fate.
Tracer Marking
The study of cell lineages was begun in the early years
of the twentieth century, shortly after the establishment of
Schwann and Schleiden’s cell theory. Lineage tracing by
directly observing living transparent invertebrate embryos,
composed of few cells, was first performed by E.G. Conklin
and others (12) [reviewed by Stern and Fraser (13)]. In
most embryos, however, direct observation is not possible.
W. Vogt then devised a method to follow cells using vital
dyes (14,15). A new improvement was introduced with the
autoradiography on slides of embryos treated with radio-
active nucleotide; Rosenquist was able to draw fate maps
of chick embryos in this manner (16). However, the remain-
ing limitations were that groups of cells, rather than sin-
Fig. 1. Immunohistochemical analysis of pancreatic buds cul-
tured in collagen gels. Two consecutive semithin sections of an
E12.5 pancreatic bud cultured for 7 d were stained with two differ-
ent antibodies: antiglucagon (A) and anticollagen IV (B). Clusters
of endocrine cells stained with antiglucagon antibody (A) migrate
from the duct-like cords of epithelial cells into the surrounding
mesenchyme. This process involves interactions between endo-
crine cells and with the extracellular matrix (ECM), through ad-
hesion molecules, and active proteolysis of the ECM, as illustrated
with the anticollagen IV staining (B). Collagen IV is a main com-
ponent of epithelial basement membranes. Digestion of collagen
IV is shown to occur at places were endocrine clusters of cells are
budding (asterisks in panel B). Scale bar is 20 µm.
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gle cells, were labeled, and, in addition, the soluble dyes or
labeled radioactive components could pass between unre-
lated adjacent neighbor cells. Several alternatives were then
found, such as the use of carbocyanine dyes (DiI and DiO),
and intracellular tracers (enzymes, like horseradish peroxi-
dase, or fluorochrome-conjugated high-molecular-weight
molecules, like dextrans), which can be directly injected into
single cells. Carbocyanine dyes are lipid-soluble and inte-
grate into the membrane of cells; they were successfully
used to trace the growth of axons. More recently, monoclo-
nal antibodies coupled to gold particles have been used to
mark cells expressing a surface antigen; because the cells
internalize the attached labeled antibody, their descendants
are also marked (17).
Genetic Marking
Injecting small single cells may prove technically diffi-
cult, but the main disadvantage, however, with vital dyes,
isotope or antibody labeling, fluorescent markers, carbocy-
anine dyes, or enzymes, is that the signal becomes diluted as
cells divide. To follow cells over long periods or complex
differentiation programs, irreversible tagging is mandatory.
Mosaics
The labeling dilution problem can be overcome by genet-
ically marking embryos through infection with replication-
deficient retroviruses bearing a gene encoding a marker (such
as -galactosidase, alkaline phosphatase, or GFP) (18–21).
The approach consists in using very few viral particles so
that infection is a rare event; therefore, marked cells in a
given infected embryo are probably clonally related. Infected
embryos are thus mosaics. The main disadvantage of this
approach, apart from the uncertainty regarding the inter-
pretation of the results, is that labeled cells are not chosen
directly; this lineage analysis is thus “retrospective.” Using
this method with pancreatic rudiments cultured in vitro,
Fishman and Melton demonstrated that a single infected
pancreatic progenitor cell is able to give rise to both exo-
crine and endocrine cells (20).
Chimeras
Another way to circumvent the problem of tracer dilu-
tion was devised as early as the 1920s, through the genera-
tion of interspecies chimeras, by transplantation (grafting)
or, much later, by aggregating two mouse embryos. Chime-
ras are derived from more than one embryo; therefore, their
body is formed of cells from different individuals, thus hav-
ing different genetic constitutions. In transplantation chi-
meras, donor and host cells can be easily distinguished for
they are morphologically different (22–26). With this method
(grafting quail neural crest cells on chick embryos), Le Doua-
rin demonstrated that neural crest cells do not contribute to
the formation of pancreatic endocrine cells (27).
In vitro grafting, i.e., tissue co-cultures of rudiments
from different embryos, is another variation of the chimera
approach. With this system, Martineau and colleagues (28)
demonstrated that there is migration of cells from the meso-
nephros into the male gonad during development, but not
into the developing ovaries. Percival and Slack (29) showed
that the pancreatic mesenchyme does not contribute to pan-
creatic cells: when labeled prepancreatic endoderm was cul-
tured with unmarked mesenchyme, only the endoderm gave
rise to acini, ducts, and islets.
Mouse aggregation chimeras, using, for instance, trans-
genic and wild-type morulae, or chimeras generated by injec-
tion of pluripotent ES cells into host blastocysts, are power-
ful tools to identify different cell populations within a single
organ in vivo. With the embryo aggregation approach, Jami
and coworkers demonstrated that pancreatic islets of Langer-
hans are of polyclonal origin, i.e., that endocrine cells within
a particular islet derive from different progenitors (30).
Transgenics
In the simplest transgenic experiment, expression of re-
porter molecules using cell-type-specific promoters (whether
exogenous or endogenous, as in knock-in mice) may be taken
as evidence for cell lineage relationships (3). This would be
valid if the progeny of labeled cells did not cease express-
ing the reporter transgene, but this is not applicable in terms
of lineage analysis. When reporter expression stops, this
method is dependent on the stability of the transgenic reporter
protein and is weakened because cell divisions imply dilu-
tion of the marker, as previously discussed. These are impor-
tant limitations because many developmentally relevant genes
are expressed only transiently. Similarly, endogenous pro-
teins, such as peptidic hormones, have been used in the past,
with the same serious flaws as lineage tracers. Co-localiza-
tion of hormones in single cells during development is not
a proof of common ontogeny.
Transgenesis resulting in mosaicism may be used for retro-
spective lineage analyses. This is possible using transgenic
mice in which a very rare spontaneous mutation activates the
expression of a reporter transgene in early embryos (31–33),
or also using X-inactivation transgenic mosaic mice, i.e., trans-
genic females bearing a X-linked reporter transgene (34–38).
Targeted oncogenesis, in transgenic mice expressing
powerful oncogenes under the control of cell-specific pro-
moters, has also been used as an approach to analyze cell
lineages in the pituitary (39,40). This method allows for im-
mortalizing rare cell types (41–43) that might recapitulate
in culture the characteristics of progenitor cells. The main
disadvantage of this conception, however, is that tumor cells
maintained in vitro are profoundly altered. Moreover, cells
in culture are not in a normal environment, and because many
genes act noncell autonomously, the effect of neighboring
cells, and vice versa, is critical, and cannot be addressed with
this approach.
Two sophisticated methods using transgenic mice have
been introduced more recently, and both were first employed
to trace pancreatic cell lineages. The first method is the
targeted ablations of given cell types using cell-type-spe-
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cific promoters to express toxin genes. The rationale is that
missing cells are derived from, or are dependent on, the cell
type destroyed, which would then be a putative precursor,
or adjuvant cell. A refinement of this approach was success-
fully used to address the enteroendocrine cell lineages through
the conditional ablation of secretin cells, upon administra-
tion of ganciclovir, in transgenic mice expressing herpes
simplex virus 1 thymidine kinase (HSVTK) under the con-
trol of a secretin promoter (44). The viral enzyme HSVTK
phosphorylates the thymidine analog ganciclovir, which is
mutagenic and cytotoxic.
The second approach is the irreversible targeted tagging
(labeling) of a given cell type using a promoter to express
Cre recombinase (Cre/loxP system) (45,46). This is the
most reliable and powerful method to trace cell lineages in
Amniota in vivo; it permits detection of descendants that do
not express the gene of interest any more (Fig. 2).
Both approaches have pioneered in pancreatic rudiment
cell lineage tracing, and will be discussed in more detail
below. We now summarize some knockout experiments that
have demonstrated a crucial role for a few genes in pancreas
development.
Fig. 2. Tracing cell lineages with the Cre/loxP strategy. In order to genetically label pancreatic progenitor cells, two different strains of
transgenic mice are needed. The “reporter mouse” bears a reporter transgene (in the cartoon the -galactosidase coding region) placed
under the control of a promoter (either tissue-specific or ubiquitous) and downstream of a loxP-flanked transcription termination cassette
(STOP sequence). The “tagger mouse” (“marker” or “deletor” mouse), has a transgene encoding the Cre recombinase gene under the
control of a cell-specific promoter, which should be active in putative pancreatic progenitor cells. In doubly transgenic mice, the
expression of the tagger transgene in a precursor cell results in the excision of the reporter’s STOP sequence, thus allowing its expression
(-galactosidase). This tag is then genetically transmitted to all the progeny of this cell and permits the tracing of its lineage during the
formation of the pancreas.
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Insights from Gene Inactivation Experiments:
Examples of Noncell Autonomous vs Cell
Autonomous Effects of Gene Expression
Inactivation of genes (gene targeting or ablation) in knock-
out (KO) mice is one way to study their function. This may
result in loss of some particular cell type(s) and/or activa-
tion of reporter gene expression (knockin mice). These
results have sometimes been considered as a means to iden-
tify precursor cells; this is conceptually wrong. Genes are
often expressed transiently: cytodifferentiation during devel-
opment is based on differential gene expression. Moreover,
many genes act noncell autonomously (i.e., in paracrine
ways); as a consequence, cell ablation following gene inac-
tivation mutations (knockout mice) cannot be taken as evi-
dence of cell lineage relationships among different cell types.
Strictly, the gene knockout experiments tell us whether a
given gene is necessary for a given cell type to differentiate
or fully mature, at the time of inactivation. On the contrary,
genetic labeling of cells is aimed at unequivocally identify-
ing the progeny of a cell that has expressed a particular gene
during differentiation.
Mesenchymal Factors Are Noncell Autonomous
Inducers of Epithelial (Endodermal) Cell Differentiation
Epithelial–mesenchymal interactions are essential for
pancreas morphogenesis and cytodifferentiation. Different
pancreatic lineages require different mesenchymal factors
for their development. For instance, when the pancreatic bud
epithelium is cultured in the absence of mesenchyme, or
grafted under the kidney renal capsule, only endocrine cells
differentiate (47). The identity of most soluble mesenchy-
mal factors remains unclear, but the TGF, FGF, and EGF
signaling pathways appear to be involved (1,4,48). The TGF
superfamily member follistatin, which is expressed in pan-
creatic mesenchyme, promotes exocrine differentiation (49),
but TGF1 has the opposite effect (50–53).
Targeted disruption of Isl1 (ISLET1, a LIM homeodo-
main protein), which is expressed in early endocrine cells,
abolishes endocrine differentiation. Isl1 is nevertheless first
expressed in the mesenchyme surrounding the dorsal pri-
mordium. In Isl1/ embryos there is no dorsal pancreatic
bud, and this is a consequence of the lack of dorsal mesen-
chyme (54).
Inactivation of the adhesion molecule N-cadherin also
results in agenesis of the dorsal pancreas, which is associated
again with a loss of dorsal mesenchyme (55). Interestingly,
Isl1 expression persists in the mesenchyme as well as in pro-
spective dorsal pancreatic epithelium, whereas Pdx-1 expres-
sion is normal by E9, but is then rapidly restricted to the
prospective ventral pancreas; because Pdx-1 is similarly dor-
sally downregulated in Isl1/ mice (54), it appears that the
dorsal mesenchyme is necessary to maintain Pdx-1 expres-
sion. In fact, in vitro recombination experiments demon-
strate that wild-type mesenchyme rescues morphogenesis
and cytodifferentiation in N-cadherin/ dorsal endoderm.
Transcription Factors in Pancreas Development (Table 1)
Even though transcription factors are likely to act cell
autonomously, the consequences of their activity indirectly
affect neighbor cells in a paracrine (noncell autonomous)
way. Many transcription factors, mostly homeobox genes,
have been mapped to specific regions of the endoderm, as
well as to the surrounding visceral mesenchyme, and are
likely to modulate the mesoderm–endoderm interactions
[reviewed by Schwitzgebel (56)]. Their involvement in pan-
creas determination, growth, and differentiation has been
assessed by their selective inactivation in mice (summarized
in Table 1). The factors that are more relevant for pancreas
development are briefly discussed herein.
PDX1 (pancreatic and duodenal homeobox-1) is, together
with the homeodomain protein HB9, the earliest marker of
pancreatic bud cells, from E8.5. PDX1 is necessary for the
development of the pancreas, as Pdx1 deficient mice have
pancreatic aplasia (57,58). However, insulin and glucagon
cells are present in early embryonic buds of Pdx1/ mice,
and their pancreatic mesenchyme develops normally. Pdx1
is not a “master control gene,” because its ectopic expres-
sion in the hindgut endoderm is not sufficient to trigger
pancreas formation (59).
The inactivation of two bHLH transcription factors, PTF1-
p48 and Ngn3, suggest that they could be implicated in deter-
mining whether an early pancreas cell is to become exocrine
or endocrine. Mice in which PTF1-p48 is inactivated have
no exocrine pancreas (60,61), whereas inactivation of Ngn3
results in agenesis of endocrine pancreas (62). In pancrea-
tic buds, NGN3 is detected in proliferating cells expressing
Table 1
Some Factors Involved in Pancreas Development,
as Determined Using KO Mice
Targeted Dorsal Ventral
gene pancreas pancreas Reference
Pdx1 Aplasia 57,58,86
Ngn3 No islets 62
PTF1-p48 No exocrine cells 60
Pax4 No  or  cells 66
Pax6 No  cells; 65
endocrine hypoplasia
Isl1 Agenesis; No endocrine 54
no mesenchyme cells
Hlxb9 Agenesis Fewer  cells 87,88
Hes1 Hypoplasia  73
N-cadherin Agenesis; Normal 55
no mesenchyme
Beta2/NeuroD Fewer  cells; 89
distorted islets
Hnf6                            Endocrine hypoplasia 90
Pbx1 Hypoplasia 91
Nkx2.2 Immature -cells 92
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PDX1, but not in hormone-containing cells. Overexpres-
sion of Ngn3 (under the control of a Pdx1 promoter, in trans-
genic mouse embryos, or of an ubiquitous promoter, in
electroporated chick embryos) is sufficient to drive differen-
tiation of glucagon cells, but not of insulin cells (56,63,64).
In the absence of the paired-box domain protein PAX6,
known to be downstream of ISL1, and initially expressed
in all pancreatic endocrine cells, the development of all endo-
crine lineages is affected (65). The PAX4 protein is specifi-
cally necessary for the production of mature  and  cells
(66). Interestingly, in Pax6/ and Pax4/ double mutants
islets are totally absent.
In summary, the gene inactivation studies show, among
many other interesting findings, that (1) several mesenchy-
mal factors, whether soluble or adhesion molecules, or tran-
scription factors, are needed for pancreas development by
activating genes in the prospective pancreatic endoderm,
(2) Pdx1 is necessary for growth of both pancreatic rudi-
ments, (3) ptf1-p48 activity is required for exocrine pancreas
differentiation, and (4) Ngn3 is necessary for the differen-
tiation of islet endocrine cells.
Together, these results suggest some gene products (ISL1,
N-Cadherin, PDX1, p48, and NGN3), whose inactivation
induces loss of cells, as candidate markers for pancreatic
progenitor cells. The KO experiments also point out the
principal role of the mesenchyme, whose absence inhibits
dorsal pancreas formation, although we know that the mes-
enchyme itself does not contribute to pancreatic cells (29).
This clearly illustrates that, even though extremely impor-
tant, gene inactivation experiments cannot be interpreted
as indicative of cell lineages because they result in cell loss.
Therefore, cells expressing these candidate genes were sub-
sequently genetically marked in transgenic mice, in order
to determine whether they give rise to the different adult
pancreatic cell types.
Characterizing Pancreatic Progenitor Cells
by Irreversibly Deleting or Marking Cell
Populations in Transgenic Mice
One approach to cell tracing experiments in vivo is the
selective ablation of specific cell types in transgenic mice
through the expression of toxin genes (44,67,68). The glu-
cagon-promoter-driven expression of a diphtheria toxin (DT)
A gene demonstrated that glucagon cells are not precursors
of insulin-producing cells, contrary to what colocalization
of both hormones in single cells during development would
suggest (3,68,69). The analyses were pursued by labeling
progenitor cells through the expression of Cre recombinase in
doubly transgenic mice (70). This method established that all
pancreatic cells derive from progenitors that do express Pdx1
(71,72). Recent studies also showed that Ngn3-expressing
cells are precursors of all islet cell types (72), and that ptf1-
p48 is surprisingly implicated not only in exocrine but also
in endocrine pancreas lineages (61).
Ablation of Islet Cells by Targeted Expression
of Hormone-Promoter-Driven Toxigenes
Direct cell lineage tracing of chosen labeled progenitor
cells in mouse embryos was not possible until the Cre/loxP
system was developed in the mid 1990s. Therefore, in order
to study the ontogenetic, or cell lineage, relationships between
the different types of endocrine cells in the islets, targeted
cell ablation was the best approach. In a transient transgenic
study, we generated embryos in which cells transcribing glu-
cagon, insulin, or PP genes were destroyed by the promoter-
targeted expression of DT A (68). If, as proposed, insulin
cells were the descendants of glucagon-producing precur-
sors, then the ablation of all glucagon-expressing cells would
preclude their differentiation. On the contrary, we unam-
biguously demonstrated that neither glucagon nor insulin
gene expressing cells are essential for the differentiation of
either  or  cells, respectively. These experiments also
indicated a close ontogenetic relationship among insulin, PP,
and somatostatin cells. Whether this requirement is through
a cell-lineage relationship or because those cells produce
paracrine or endocrine factors necessary for their differen-
tiation from undefined precursors, remains undetermined.
Islet Cell Lineage Analyses
by Irreversibly Labeling Cell Progenitors (Fig. 2)
Developments in gene recombination technology allowed
only recently setting up an approach to “mark” irreversibly
cells at one developmental stage using the promoter of a
given candidate marker gene, and therefore to identify all
their descendants when the promoter is no longer active.
In the context of our work, this involved the genetic
labeling of cells that transcribe Pdx1, Ngn3, Pax6, gluca-
gon, insulin, or PP genes early during development, and the
analysis of islet  and  cells, or the total pancreas, later in
development or in the adult, to determine whether they are
derived from these early Pdx1, Ngn3, Pax6, glucagon, insu-
lin, or PP gene-expressing cells [Fig. 3 and material in prep-
aration (70)]. To study the cell lineages of the endocrine
pancreas, we used a silent loxP-bearing reporter transgene
that is “activated” in a tissue-specific manner through the
activity of Cre recombinase made from a second tagger
Fig. 3. Pancreatic cell lineage analyses. To study the cell lineages of pancreatic cells, we used, as reporter mice, the R26R strain (74),
and five different transgenic mice as taggers: Pdx1-cre (70,71) (A, B), Ngn3-cre (P.L.H., unpublished results) (C, D), Pax6-cre (85) (E,
F), glucagon-cre (70) (G, H), and insulin-cre (70) (I, J), among others. PDX1 is an early marker of pancreatic bud cells (E8.5) and is
also found in the duodenal wall. In Pdx1-cre/R26R doubly transgenic embryos (A, B), -galactosidase staining is found from E9.5
in the dorsal and ventral pancreatic buds and in the future duodenum (A, an E11.5 embryo is shown). In adults, the entire pancreas and
many duodenal cells are stained (B). These results demonstrate that Pdx1+ cells and their progeny participate in the formation of these
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Fig. 3. (Continued).  two organs, and are pancreatic progenitor cells. NGN3 and PAX6 are shown to be essential for islet morphogenesis
(Table 1), and are expressed early (from E9.5) in pancreatic development. In Ngn3-cre/R26R (C, D) and Pax6-cre/R26R (E, F) mice,
-galactosidase activity is shown in dorsal pancreatic buds (C, E10.5; E, E11.5), and in all endocrine cells forming the adult islets
(D, F), demonstrating that NGN3+ and PAX6+ cells are endocrine progenitor cells. In glucagon-cre/R26R (G, H) and insulin-cre/R26R
(I, J) mice, -galactosidase staining is found in pancreatic buds at E11.5 and earlier (G, I; E11.5 embryos are shown), and in  cells (H)
and  cells (J) in mature islets, respectively. (Note in panel H that only peripheral islet  cells are blue.) All these results illustrate the
power of the Cre/loxP strategy to study cell lineages. d, duodenum ; db, dorsal bud ; s, stomach ; vb, ventral bud. Scale bars are 0.25 mm
in A, C, E, G, H, and I; 1 mm in B, D, F, and J.
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transgene (73). The experimental design thus consists in
generating mice bearing two transgenes (summarized in
Fig. 2). One transgene, “reporter,” placed under the control
of either tissue-specific (70) or ubiquitous promoters (61,
71,72,74–76), contains either the human growth hormone
(hGH) (70), -galactosidase (77), human alkaline phospha-
tase (71,75), or EGFP (76) coding region placed downstream
of a “floxed” (i.e., loxP-flanked) transcription termination
site (STOP sequence) (78–80). Expression of the native
reporter transgene requires the deletion of this sequence,
which is obtained in the presence of Cre recombinase.
The tagger transgene consists of the Cre recombinase gene
placed under the control of a promoter (transgenic or endog-
enous, as in knockin mice) active in putative progenitor
cells; its expression results in the irreversible deletion of the
STOP (blocking) sequence of the reporter transgene, thereby
allowing their expression, and thus labeling all progeny
derived from those progenitors that express the tagger. Others
have used this approach to activate the transcription of SV40
T antigen, LacZ, or placental alkaline phosphatase genes
in transgenic mice (73,79,80), and to analyze the life span
of circulating memory T cells (78), but not to trace cell
lineages.
Using this genetic approach, which allows following
cell lineages through the expression of Cre recombinase, it
was first shown that islet - and -cell lineages appear to
arise independently during ontogeny from a common Pdx1-
expressing precursor [Fig. 3A and B; Fig. 4 (70)]. The cell
ablation results (68) were thus confirmed and, in addition,
it was discovered that the insulin cell lineage express the
PP gene transiently, and that glucagon cells, which do not
express Pdx1, actually descend from PDX1+ progenitors.
This observation, combined with the fact that glucagon cells
are present in early pancreatic buds in Pdx1/ embryos, is
illustrative of the different nature of early (embryonic) and
mature (islet) glucagon cells.
A newly available ubiquitous reporter mouse, R26R, made
it possible to analyze all pancreatic cell lineages (71,72,74).
These studies confirmed that Pdx1 is expressed, at least
transiently, in all pancreatic cell types (71), and that all islet
endocrine cells derive from progenitors having transiently
expressed Ngn3 [P.L.H. unpublished observations; Figs.
3C–D and 4 (72)].
The Cre-loxP system was initially devised to inactivate
genes in selected tissues, rather than in the whole organism
(45,46). A subsequent refinement of this system allowed
Fig. 4. Schematic representation of endodermal cell lineages as deduced from the Cre/loxP-mediated irreversible labeling of precursor
cells. Liver, pancreas, and intestine derive from the same embryonic layer, the endoderm. Several reports show that Pdx1 and p48
transcription factors are expressed in early presumptive pancreatic endodermal cells that are the progenitors of the entire pancreas
(61,71,72). p48 has been reported to be restricted later to the exocrine progenitor cells. Ngn3, which is expressed from E9.5 in early ducts
or cords, has been demonstrated to be expressed in the progenitors of endocrine cells [(72); present report, Figs. 3C and D]. Pax6, another
transcription factor acting downstream of Pdx1, p48, and Ngn3, has also been shown to be expressed in endocrine progenitor cells [(85);
present report, Figs. 3E and F]. That glucagon-producing cells represent an independent lineage was shown in two different reports
[(68,70); present report, Fig. 3H, in which a glucagon-cre transgene labels only cells]. Insulin-containing  cells derive from PP-
expressing progenitors, which are also required for the differentiation of somatostatin-containing  cells (68), either directly or noncell
autonomously.
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the exquisite temporal control of the recombinant activity
of Cre in selected cells. One of these approaches consists
of a fusion enzyme, Cre-ERT, in which the ligand-binding
domain of a mutated estrogen receptor (ERT) that recognizes
the antiestrogen tamoxifen (hydroxytamoxifen, 4-OHT),
has been fused to Cre. In the absence of 4-OHT, Cre-ERT
remains in the cytoplasm. Administration of 4-OHT results
in its migration into the nucleus, as expected for a steroid
hormone receptor/ligand complex. Accordingly, Cre-medi-
ated recombination of genomic DNA is 4-OHT-dependent
in mice bearing a Cre-ERT transgene (81,82). Because 4-
OHT is active for less than 48 h in mouse embryos, Gu
and co-workers were able to pulse labeling Ngn3- or Pdx1-
expressing cells during 1–2 d windows of development by
using Ngn3-CreERT and Pdx1-CreERT transgenes. The
results with the latter transgene were unexpected, for early
labeling (at E8.5) marked only acinar and islet cells, but not
ducts; indeed, duct cells were labeled only when 4-OHT was
administered between E9.5 and E11.5. At E12.5, or later,
only acini and islets were marked. This indicates that ducts
develop independently of Pdx1 activity after E12.5; in accor-
dance with this interpretation, another elegant study in which
pancreas development is modulated with doxycycline through
activation or inactivation of Pdx1 activity, also points to a
Pdx1-independent ductal development after this stage (83).
The presence of NGN3+ cells in the adult islet was also
demonstrated in Ngn3-CreERT transgenics. Such cell
population might contribute to the maintenance of the adult
islet mass (72).
Ptf1-p48 inactivation suggested that this gene is required
for exocrine pancreas development (60). To trace the lin-
eage of Ptf1-p48-expressing cells, Kawaguchi et al. (61)
placed the Cre recombinase under the control of the endog-
enous Ptf1-p48 promoter in a knockin experiment. Surpris-
ingly, nearly all acinar, ductal, and insular cells expressed
the ubiquitous reporter transgene in heterozygous Ptf1-
p48-cre mice, indicating that Ptf1-p48 expression does not
commit precursors to exocrine lineages, but to all pancre-
atic cell fates (Fig. 4). In homozygous animals, the pheno-
type was similar to that observed in Ptf1-p48-deficient mice
(60), and, in addition, suggested that in the absence of
PTF1-p48, pancreatic cells may revert to an intestinal epi-
thelial fate. In summary, this result indicates that Ptf1-p48,
like Pdx1, is expressed in the exocrine (acinar and ductal)
and endocrine cell lineages of the pancreas, and is silenced
in endocrine and duct cells shortly after they are committed.
Conclusions and Prospective
Understanding pancreatic morphogenesis and cell dif-
ferentiation has obvious clinical implications. The poten-
tial to form pancreatic endocrine tissue, whether from stem
or differentiated cells, located in ducts or elsewhere in the
pancreas (or even in extrapancreatic tissues), should not be
restricted to the period of embryonic development. After
experimental injury, whether surgical (partial pancreatec-
tomy, duct ligation) or chemical (such as streptozotocin
or exendin-4 treatment), formation of new islets in adult
rodents occurs with some efficiency. Pdx1 is expressed in
pancreatic ductal cells during regeneration (84), as is ex-
pressed in early pancreatic buds during development (57).
However, we still must determine whether differentiation
of new islets in the adult recapitulates the events taking
place during development. In this context, the power and
elegance of the Cre/loxP-based approach to track cell line-
ages also reside in the versatility of the transgenic mice
encoding Cre recombinase in different subsets of pancre-
atic cell types. Thus, in order to address these challenging
questions, after these mice have been used to determine
cell lineage relationships during development, they are now
unique tools to address the lineages during adult regenera-
tion (neogenesis) and to inactivate specific genes in these
same pancreatic cell lineages (“conditional” KO mice).
In conclusion, the Cre/loxP lineage tracing approach
allows a better characterization of progenitor cells not only
for the pancreas, but also for any organ. Improvement of
this fundamental knowledge, i.e. the understanding of our
body’s cell lineages, should be of help to devise, in the
future, new sources of replacement tissues to treat degener-
ative diseases resulting from massive cell demise.
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